دورية أكاديمية
Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients
| العنوان: | Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients |
|---|---|
| المؤلفون: | Laura Thümmler, Anja Gäckler, Maren Bormann, Sandra Ciesek, Marek Widera, Hana Rohn, Neslinur Fisenkci, Mona Otte, Mira Alt, Ulf Dittmer, Peter A. Horn, Oliver Witzke, Adalbert Krawczyk, Monika Lindemann |
| المصدر: | Vaccines, Vol 10, Iss 8, p 1348 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | ELISpot, T cells, vaccination, Medicine |
| الوصف: | In kidney transplant (KTX) patients, immune responses after booster vaccination against SARS-CoV-2 are inadequately examined. We analyzed these patients a median of four months after a third/fourth vaccination and compared them to healthy controls. Cellular responses were analyzed by interferon-gamma (IFN-γ) and interleukin-2 (IL-2) ELISpot assays. Neutralizing antibody titers were assessed against SARS-CoV-2 D614G (wild type) and the variants alpha, delta, and omicron by a cell culture-based neutralization assay. Humoral immunity was also determined by a competitive fluorescence assay, using 11 different variants of SARS-CoV-2. Antibody ratios were measured by ELISA. KTX patients showed significantly lower SARS-CoV-2-specific IFN-γ responses after booster vaccination than healthy controls. However, SARS-CoV-2-specific IL-2 responses were comparable to the T cell responses of healthy controls. Cell culture-based neutralizing antibody titers were 1.3-fold higher in healthy controls for D614G, alpha, and delta, and 7.8-fold higher for omicron (p < 0.01). Healthy controls had approximately 2-fold higher concentrations of potential neutralizing antibodies against all 11 variants than KTX patients. However, more than 60% of the KTX patients displayed antibodies to variants of SARS-CoV-2. Thus, KTX patients should be partly protected, due to neutralizing antibodies to variants of SARS-CoV-2 or by cross-reactive T cells, especially those producing IL-2. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 10081348 2076-393X |
| العلاقة: | https://www.mdpi.com/2076-393X/10/8/1348Test; https://doaj.org/toc/2076-393XTest |
| DOI: | 10.3390/vaccines10081348 |
| الوصول الحر: | https://doaj.org/article/d7842fb028ac43d3af732d8512336939Test |
| رقم الانضمام: | edsdoj.7842fb028ac43d3af732d8512336939 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 10081348 2076393X |
|---|---|
| DOI: | 10.3390/vaccines10081348 |